Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
One-year open-label trial of canakinumab in young children with CAPS, including effects on childhood vaccinations
2009-016859-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in cryopyrin-associated periodic syndrome (CAPS), sponsored by Novartis. Primary endpoints: Primary: Treatment response, safety and tolerability in CAPS patients 4 years and younger, Primary: Treatment response in CAPS patients 2 years and younger and 1 more. Started Jun 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
cryopyrin-associated periodic syndrome (CAPS)
Beyond the preview
Go deeper on 2009-016859-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016859-22.